Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2023 - Issue
Submit an article Journal homepage
393
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Experience of Treating Chronic Obstructive Pulmonary Disease with Triple Therapy

Kuang-Ming Liao1 Department of Internal Medicine, Chi Mei Medical Center, Chiali, TaiwanORCID Iconhttps://orcid.org/0000-0003-4364-8248
ORCID Icon,
Jhi-Joung Wang2 Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan;3 Department of Anesthesiology, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan
&
Chung-Han Ho2 Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan;4 Department of Information Management, Southern Taiwan University of Science and Technology, Tainan, Taiwan;5 Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5925-8477
ORCID Icon
Pages 1057-1066 | Received 08 Jan 2023, Accepted 28 May 2023, Published online: 07 Jun 2023

References

  • Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
  • Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929.
  • Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2- agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
  • Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015;70(6):519–527.
  • Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438–446.
  • Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: results of Two Randomized, Double-Blind Studies. COPD. 2016;13(1):1–10.
  • Lipson DA, Barnhart F, Brealey N, et al.; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.
  • Rabe KF, Martinez FJ, Ferguson GT, et al.; ETHOS Investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48.
  • Suissa S, Dell’Aniello S, Ernst P. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: real-World Effectiveness on Mortality. COPD. 2022;19(1):1–9.
  • Suissa S, Dell’Aniello S, Ernst P. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort Study in Real-World Clinical Practice. Chest. 2020;157(4):846–855.
  • Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018;33(34):e213.
  • Gerhard N. Anatomical Therapeutic Chemical Classification System (ATC). Dictionary of Pharmaceutical Medicine. Vienna: Springer; 2009:8.
  • Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826.
  • Ashdown HF, Smith M, McFadden E, Pavord ID, Butler CC. Mona Bafadhel. ERJ Open Res. 2022;8:00606–2021.
  • Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756.
  • Rogliani P, Calzetta L. Mortality in ETHOS: a Question of “Power”. Am J Respir Crit Care Med. 2021;203(7):926–927.
  • Rabe KF, Hurd S, Anzueto A, et al.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555.
  • Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993;103(2):536–540.
  • Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–393.
  • Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;133(1):14–20.
  • Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis. 1979;119(6):895–902.
  • Drummond MB, Wise RA, John M, Zvarich MT, McGarvey LP. Accuracy of death certificates in COPD: analysis from the TORCH trial. COPD. 2010;7(3):179–185. doi:10.3109/15412555.2010.481695
  • McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–415.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.